Ignite Creation Date:
2024-05-06 @ 6:29 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05680818
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2022-12-12
Brief Title:
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Sponsor:
Calcilytix Therapeutics Inc a BridgeBio company
Organization:
Calcilytix Therapeutics Inc a BridgeBio company
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Autosomal Dominant Hypocalcemia ADH |
Keywords:
| Name | View |
|---|---|
| Autosomal Dominant Hypocalcemia Type 1 ADH1 | View |
| Hypocalcemia | View |
| Musculoskeletal Diseases | View |
| Muscular Diseases | View |
| Musculoskeletal Abnormalities | View |
| Calcium Metabolism Disorders | View |
| Metabolic Diseases | View |
| Hypoparathyroidism | View |
| Hypocalcemic Seizures | View |
| Hypercalciuria | View |
| Nephrocalcinosis | View |
| Nephrolithiasis | View |
| Calcium Sensing Receptor | View |
| Encaleret | View |
| Hypopara | View |